Press Releases

MONTCLAIR, NJ

Listening To Spravato LLC, a clinical-music research company, today announced an expansion of its research program to investigate Compass Pathways' proprietary compound, COMP360 — the 360th compound studied by Compass Pathways and a potential alternative or complement to SPRAVATO® (esketamine) for treatment-resistant depression.

As the first clinical-music company to establish therapeutic sound design protocols for esketamine treatment, Listening To Spravato™ has built a body of work used across thousands of treatment sessions in the United States. Its protocols govern the design and integration of music systems for the full arc of the SPRAVATO® experience — from the preparatory Onset phase through the dissociative Peak and into the re-integrative Return. As COMP360 and similar compounds move toward clinical use, those protocols will need to evolve.

"The application of SPRAVATO® involves a unique sensory experience that a patient can verbally describe as sound or music," said Justin Page, founder of Listening To Spravato LLC. "Like SPRAVATO®, each dissociative profile will have a unique sound architecture that reflects that compound's sensory experience. Clinical music can't be interchanged for a different compound. Each compound has to be developed independently."

Differences in how COMP360 produces dissociation — including the speed of onset, the emotional character of the peak state, and the depth of perceptual alteration — will directly affect the safe-use parameters for clinical music. If COMP360 produces psychedelic-like effects beyond those typical of SPRAVATO®, the music used during treatment will need to be designed to manage that expanded sensory profile, not simply adapted from existing esketamine playlists.

Listening To Spravato LLC is currently conducting research into the potential auditory needs of COMP360 treatment, including descriptions of COMP360 sensory experiences, clinically safe soundscapes, preferred auditory experiences, and the integration of music psychotherapy frameworks appropriate for psychedelic-adjacent states. The company is also developing requirements for multi-modal treatment room design — the acoustic and audiovisual infrastructure that will be needed to support next-generation dissociative therapies.

Looking further ahead, Listening To Spravato LLC anticipates that treatment centers will increasingly need clinical-music systems capable of supporting multiple compounds simultaneously — each with its own sensory profile and its own evidence-based playlist architecture. "Our goal is to supply treatment centers with music that provides patients undergoing various therapies with a safe, dependable, and clinically appropriate auditory environment," Page said. "If Compass becomes a competing product to SPRAVATO®, Listening To LLC would develop evidence-based clinical-music solutions for it."

SPRAVATO® was the first treatment to establish and protect patients' right to music as part of the therapeutic experience. Compass may be the second. The architecture to support that right — the protocols, the phase frameworks, the safety evaluations, and the engineering standards — is already being built by Listening To Spravato LLC.

"Clinical music can't be interchanged for a different compound. Each compound has to be developed independently."

# # #